Organization
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
7 abstracts
Abstract
Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.Org: ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, Ministry of Health, Kogarah, NSW, Australia, AbbVie, North Chicago, IL, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy,
Abstract
Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.Org: Vanderbilt-Ingram Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, University of Texas MD Anderson Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV - IRCCS,
Abstract
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.Org: Institut Gustave Roussy, Hospital Universitario y Politecnico La Fe, ICO-Hospital Germans Trias i Pujol, Medical University of Gdansk, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.Org: University of Texas MD Anderson Cancer Center, Veneto Institute of Oncology IOV - IRCCS, Hospital Universitario 12 de Octubre, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.Org: Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori – IRCCS Fondazione G. Pascale, Napoli, Italy, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Istituto Nazionale Tumori - IRCCS Fondazione Pascale, Medical Oncology Unit. Comprehensive Cancer Center. AUSL-IRCCS Reggio Emilia, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.Org: Fondazione Poliambulanza Istituto Ospedaliero 57, Brescia, Italy, Hospital de Sant Pau, Barcelona, Spain, Royal Marsden, London, United Kingdom, Department of General, Digestive, and Endocrine Surgery, Nouvel Hôpital Civil, Strasbourg, France, Hellenic Anticancer Hospital 'Saint Savvas', Athens, Greece,
Abstract
A VIRTUOUS IMPLEMENTATION OF TELEMEDICINE SERVICES IN RHEUMATOLOGY: DESCRIPTION OF CHANGE MANAGEMENT PRACTICES ADOPTED BY THE NIGUARDA HOSPITALOrg: Cergas SDA Bocconi, Bocconi University, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, Rheumatology Unit, University of Pisa Radiology Unit, Pisa University Hospital, Pisa, Italy,